Comparative Efficacy of Peptides vs. Traditional Anabolics

Where each compound acts

Peptides and traditional anabolics are often compared as weaker and stronger versions of the same drug. Mechanistically, they aren't. Anabolic-androgenic steroids (AAS) such as testosterone bind the androgen receptor inside muscle cells. The growth hormone secretagogues lifters mostly use (CJC-1295 and ipamorelin) act two steps upstream. They prompt the pituitary to release growth hormone (GH), which in turn raises IGF-1. BPC-157 and TB-500 belong to a third group, thought to act on local repair signals in injured tissue, based almost entirely on animal work.

Where a compound acts predicts a lot about what it can do. A drug that binds the target receptor can push the signal about as far as the dose goes. One that works through the body's own hormone release runs into feedback loops. And when a mechanism has only been seen in rats, nobody can yet say how big the effect is in people. Our overview of peptide mechanisms covers peptide signaling more generally.

Androgen receptor signaling: direct and dose-dependent

The androgen receptor is a transcription factor: once testosterone binds it, the receptor moves into the nucleus and switches genes on or off. A 2016 review in Clinical Biochemist Reviews describes it as widely expressed, with roles in tissues from muscle and bone to the heart and blood. The drug can't pick which receptors it reaches. Muscle effects and side effects arrive together.

In a 1996 randomized trial in the New England Journal of Medicine, 43 healthy men received weekly injections of 600 mg of testosterone enanthate or placebo for 10 weeks. Men who got testosterone and lifted weights gained 6.1 kg of fat-free mass. Even the testosterone group that didn't train gained more muscle size and strength than placebo.

A 2001 trial by the same group first switched off the testosterone production of 61 young men with a drug. They then received weekly testosterone enanthate for 20 weeks, at one of five doses between 25 and 600 mg. Fat-free mass rose with the dose, from about 3.4 kg at 125 mg a week to 7.9 kg at 600 mg. HDL cholesterol fell as the dose rose, while hemoglobin went up. Both trials used supervised research doses, not protocols for lifters.

Androgens also feed back on the brain. The hypothalamus and pituitary treat high androgen levels as a cue to cut the hormones that drive the testes. Natural testosterone output falls. A 2014 review in Fertility and Sterility calls the resulting hypogonadism a potential consequence of AAS use that may depend on dose and duration, though it found no studies good enough to pool.

The GH/IGF-1 axis: two steps removed

CJC-1295 is a long-acting analog of growth hormone releasing hormone (GHRH) and binds the GHRH receptor on pituitary cells. Ipamorelin binds a different pituitary receptor, the ghrelin receptor (GHSR-1a). Both increase pulsatile release of the body's own GH. GH then acts on the liver and other tissues, which make IGF-1. IGF-1 and somatostatin feed back to restrain further release, so the body's own controls shape the response, not the dose alone.

The human evidence for these two peptides measures hormones, not muscle. In the first of two placebo-controlled 2006 trials in healthy adults aged 21 to 61, single subcutaneous doses of CJC-1295 (30 to 250 mcg/kg) raised average GH 2- to 10-fold for six days or more. IGF-1 rose 1.5- to 3-fold for 9 to 11 days. Neither trial measured muscle. Ipamorelin's main efficacy trial, a 2014 Phase 2 study, was in bowel surgery. Its 117 patients got 0.03 mg/kg by IV infusion twice daily for up to 7 days to speed gut recovery, and did no better than placebo. On this site's evidence scale, both peptides rate moderate, with some human data and none on body composition.

A better test is what happens when GH itself goes up. A 2008 systematic review in Annals of Internal Medicine pooled 27 study samples covering 303 young, fit adults given GH directly. The average dose was 36 mcg/kg a day, for about 20 days on average. Lean body mass rose 2.1 kg over controls. Strength and exercise capacity didn't seem to improve. Soft-tissue swelling was more common, so some of that lean mass may be fluid.

MK-677 is an oral non-peptide that acts on the same ghrelin receptor as ipamorelin. A two-year trial gave 25 mg a day to 65 healthy adults aged 60 to 81. Fat-free mass rose 1.1 kg, against a 0.5 kg loss on placebo, with no change in strength or function. Total fat mass didn't change. Fasting glucose rose and insulin sensitivity fell.

The next step is an untested inference. If GH itself adds about 2 kg of lean mass without more strength, a peptide raising GH within the body's limits probably won't beat it. Our explainer on the growth hormone pathway has more on the axis.

Local repair pathways: a plausible mechanism, mostly in rats

BPC-157 and TB-500 rest on a different idea: faster repair in the injured tissue itself, partly through angiogenesis (new blood vessel growth) in tissue with a poor blood supply, like tendon.

A 2003 rat study from the University of Zagreb cut the Achilles tendon and gave BPC-157 by daily intraperitoneal injection, at doses from 10 pg/kg to 10 mcg/kg. Over 14 days, treated rats had stronger tendons and better function than rats given saline. Much of the BPC-157 literature comes from that same Zagreb group.

Human data are thin. A 2025 systematic review in the HSS Journal found 36 relevant studies, and 35 were preclinical. In the one clinical study, a retrospective series, 7 of 12 people with chronic knee pain reported relief lasting over six months after a knee injection. The reviewers found no clinical safety data. BPC-157's evidence rates emerging on this site's scale. As of October 2026, no controlled human trial has reported whether it heals tendons. The first credible registered one is a University of Arkansas pilot of about 30 people after rotator cuff repair. It plans 90 days of daily subcutaneous BPC-157 or placebo, starting in January 2027 according to its record.

TB-500 has even less. It isn't the full 43-amino-acid thymosin beta-4 protein. It's a 7-amino-acid acetylated fragment (Ac-LKKTETQ) that a Belgian doping-control lab identified in TB-500 products in 2012. As of October 2026, FDA's compounding safety list says the agency has found no human exposure data for this fragment. Human trials of full thymosin beta-4 don't show what the fragment does. TB-500 rates preliminary.

Users report mixed results with both peptides for stubborn tendon problems: some describe clear improvement within weeks, while others notice nothing. Without a controlled trial, those reports can't separate the peptide from natural healing or expectation, and gray-market product quality varies.

No trial shows that AAS heal tendons either, and observational data point the other way. A 2015 study took medical histories from 142 experienced male bodybuilders aged 35 to 55. Of the 88 long-term AAS users, 22% reported at least one tendon rupture, against 6% of non-users (hazard ratio 9.0). Histories were self-reported, and the design can't prove cause.

What the mechanism predicts

Because these pathways don't compete for one receptor, many lifters combine AAS with GH secretagogues or repair peptides. No controlled study has tested those combinations. On paper the risks add up: androgen effects on cholesterol plus the glucose changes seen with MK-677. Our page on peptides versus steroids for building muscle covers the muscle side of that question.

The World Anti-Doping Agency (WADA) sorts these compounds by mechanism too. Its 2026 Prohibited List puts AAS under S1.1 and the GH-releasing compounds CJC-1295 and ipamorelin under S2.2.4. TB-500 sits under S2.3 growth factors as a thymosin beta-4 derivative, while BPC-157 is named under S0. As of October 2026 all are banned at all times for tested athletes; see our guide to WADA's peptide rules.

What we still don't know

• Whether BPC-157 changes tendon healing in people. The Arkansas pilot would be the first credible placebo-controlled test, and with about 30 participants it can give only a rough signal.
• Whether CJC-1295 or ipamorelin adds measurable muscle or strength in young, trained adults. No trial has measured it, and the GH data above suggest any gain would be small.